Advertisement

Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients

  • Sanjana Ayyagari
  • Mimi C. Tan
  • Yan Liu
  • Hashem B. El-Serag
  • Aaron P. ThriftEmail author
Original Article

Abstract

Background

Acid-suppressant medications, including proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs), are frequently prescribed and have been linked to increased risk of some gastrointestinal cancers.

Aims

We examined whether post-diagnosis use of PPIs/H2RAs is associated with the risk of mortality in gastrointestinal cancer patients.

Methods

We used data from patients with esophageal cancer, gastric cancer, or hepatocellular carcinomas (HCCs) in the national VA Central Cancer Registry diagnosed between 2002 and 2016. We identified PPI/H2RA prescriptions that were filled before and after cancer diagnosis and used time-dependent Cox regression models to calculate adjusted hazard ratios (HRs) and 95% CIs for mortality risk. We used a time-varying exposure to avoid immortal-time bias and a 3-month lag to reduce reverse causation. A sensitivity analysis was conducted varying the lag duration between the date of cancer diagnosis and the start of follow-up.

Results

PPIs were used by the majority (54% post-diagnosis use) of patients. We found no association between post-diagnosis PPI use and cancer-specific mortality in esophageal adenocarcinoma (HR 0.93; 95% CI 0.84–1.02), esophageal squamous cell carcinoma (HR 0.99; 95% CI 0.87–1.12), or gastric cardia cancer (HR 1.04; 95% CI 0.89–1.22) patients. Post-diagnosis PPI use was, however, associated with the increased risk of cancer-specific mortality for patients with gastric non-cardia cancer (HR 1.50; 95% CI 1.29–1.74) and HCC (HR 1.31; 95% CI 1.23–1.40). The results were similar for associations with post-diagnosis use of H2RAs. There was no association with pre-diagnosis PPI/H2RA use.

Conclusion

Post-diagnosis PPI/H2RA use was associated with the increased mortality in gastric non-cardia cancer and HCC patients.

Keywords

Cancer Mortality Prognosis Acid-suppressant medication use 

Notes

Author’s contribution

APT was involved in study concept and design. APT and YL performed statistical analysis and interpretation of data. HES and APT were involved in acquisition of data and obtained funding. YL prepared the data. SA, MCT, HES, and APT drafted the manuscript. SA, MCT, YL, HES, and APT were involved in critical review of the manuscript for important intellectual content. All authors read and approved the final version for submission.

Financial support

This work was supported in part by National Institutes of Health grant P30 DK056338 (Study Design and Clinical Research Core), which supports the Texas Medical Center Digestive Diseases Center. This research was supported in part with resources at the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413), at the Michael E. DeBakey VA Medical Center, Houston, TX. The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the United States government or Baylor College of Medicine.

Compliance with Ethical Standards

Conflict of interests

None.

Supplementary material

10620_2019_5984_MOESM1_ESM.docx (21 kb)
Supplementary material 1 (DOCX 21 kb)

References

  1. 1.
    Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23:3155–3162.CrossRefGoogle Scholar
  2. 2.
    Wang Z, Graham DY, Khan A, et al. Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. Int J Epidemiol. 2018;47:966–975.CrossRefGoogle Scholar
  3. 3.
    Anderson WF, Rabkin CS, Turner N, et al. The changing face of noncardia gastric cancer incidence among US non-Hispanic Whites. J Natl Cancer Inst. 2018;110:608–615.CrossRefGoogle Scholar
  4. 4.
    White DL, Thrift AP, Kanwal F, et al. Incidence of Hepatocellular Carcinoma in All 50 United States, from 2000 through 2012. Gastroenterology. 2017;152:812–820.e5.CrossRefGoogle Scholar
  5. 5.
    Surveillance E, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 9 Regs Research Data, Nov 2014 Sub (1973-2012) <Katrina/Rita Population Adjustment>—Linked To County Attributes—Total U.S., 1969–2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission.
  6. 6.
    Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD an overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59:135–153.CrossRefGoogle Scholar
  7. 7.
    Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018;53:172–177.CrossRefGoogle Scholar
  8. 8.
    Brusselaers N, Wahlin K, Engstrand L, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7:e017739.CrossRefGoogle Scholar
  9. 9.
    Cheung KS, Chan EW, Wong AYS, et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67:28–35.CrossRefGoogle Scholar
  10. 10.
    Tran KT, McMenamin UC, Hicks B, et al. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. Aliment Pharmacol Ther. 2018;48:55–64.CrossRefGoogle Scholar
  11. 11.
    Shao YJ, Chan TS, Tsai K, et al. Association between proton pump inhibitors and the risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;48:460–468.CrossRefGoogle Scholar
  12. 12.
    Kao WY, Su CW, Chia-Hui Tan E, et al. Proton pump inhibitors and risk of hepatocellular carcinoma in patients with chronic hepatitis B or C. Hepatology. 2019;69:1151–1164.CrossRefGoogle Scholar
  13. 13.
    Jackson GL, Melton LD, Abbott DH, et al. Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs. J Clin Oncol. 2010;28:3176–3181.CrossRefGoogle Scholar
  14. 14.
    Zullig LL, Jackson GL, Dorn RA, et al. Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. Mil Med. 2012;177:693–701.CrossRefGoogle Scholar
  15. 15.
    Sohn MW, Arnold N, Maynard C, et al. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4:2.CrossRefGoogle Scholar
  16. 16.
    Davila JA, Duan Z, McGlynn KA, et al. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol. 2012;46:71–77.CrossRefGoogle Scholar
  17. 17.
    Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470.CrossRefGoogle Scholar
  18. 18.
    Levesque LE, Hanley JA, Kezouh A, et al. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.CrossRefGoogle Scholar
  19. 19.
    Targownik LE, Suissa S. Understanding and avoiding immortal-time bias in gastrointestinal observational research. Am J Gastroenterol. 2015;110:1647–1650.CrossRefGoogle Scholar
  20. 20.
    Zhou Z, Rahme E, Abrahamowicz M, et al. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol. 2005;162:1016–1023.CrossRefGoogle Scholar
  21. 21.
    Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999;20:145–157.CrossRefGoogle Scholar
  22. 22.
    Xie Y, Bowe B, Li T, et al. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7:e015735.CrossRefGoogle Scholar
  23. 23.
    Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365:l1580.CrossRefGoogle Scholar
  24. 24.
    Tvingsholm SA, Dehlendorff C, Osterlind K, et al. Proton pump inhibitor use and cancer mortality. Int J Cancer. 2018;143:1315–1326.CrossRefGoogle Scholar
  25. 25.
    Papagerakis S, Bellile E, Peterson LA, et al. Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res (Phila). 2014;7:1258–1269.CrossRefGoogle Scholar
  26. 26.
    Miftahussurur M, Yamaoka Y, Graham DY. Helicobacter pylori as an oncogenic pathogen, revisited. Expert Rev Mol Med. 2017;19:e4.CrossRefGoogle Scholar
  27. 27.
    Tan MC, Graham DY. Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer. BMJ Evid Based Med. 2018;23:111–112.CrossRefGoogle Scholar
  28. 28.
    Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831.CrossRefGoogle Scholar
  29. 29.
    Fais S, Venturi G, Gatenby B. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastasis Rev. 2014;33:1095–1108.CrossRefGoogle Scholar
  30. 30.
    Caplin M, Khan K, Savage K, et al. Expression and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma. J Hepatol. 1999;30:519–526.CrossRefGoogle Scholar
  31. 31.
    Kucuk HF, Akyol H, Kaptanoglu L, et al. Effect of proton pump inhibitors on hepatic regeneration. Eur Surg Res. 2006;38:322–328.CrossRefGoogle Scholar
  32. 32.
    Shi JH, Line PD. Effect of liver regeneration on malignant hepatic tumors. World J Gastroenterol. 2014;20:16167–16177.CrossRefGoogle Scholar
  33. 33.
    Morgan RO, Petersen LA, Hasche JC, et al. VHA pharmacy use in veterans with Medicare drug coverage. Am J Manag Care. 2009;15:e1–e8.PubMedGoogle Scholar
  34. 34.
    Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13:594–601.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Section of Epidemiology and Population Sciences, Department of MedicineBaylor College of MedicineHoustonUSA
  2. 2.Section of Gastroenterology and Hepatology, Department of MedicineBaylor College of MedicineHoustonUSA
  3. 3.Center for Innovations in Quality, Effectiveness and Safety (IQuESt)Michael E DeBakey Veterans Affairs Medical CenterHoustonUSA
  4. 4.Dan L Duncan Comprehensive Cancer CenterBaylor College of MedicineHoustonUSA

Personalised recommendations